
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics Inc. has demonstrated strong financial performance, with a notable 57% year-over-year increase in revenue, driven by a higher mix of new prescriptions (NPS) within the pharmacy channel. The company has raised its 2025 and 2026 revenue estimates to $97.5 million and $136 million, respectively, alongside significant increases in quarterly forecasts due to robust demand and sales momentum. Additionally, management has updated their fiscal year 2025 guidance, reflecting confidence in maintaining a strong growth trajectory, with expectations of a 30-40% compound annual growth rate from 2024 to 2028.
Bears say
Beta Bionics Inc faces significant challenges that contribute to a negative outlook for its stock. Key issues include the potential failure to gain market share with its iLet Bionic Pancreas launch, increased competitive pressure, and delays in clinical development timelines that may hinder the company's ability to penetrate the pharmacy channel. Additionally, the lack of an FDA label for Type 2 diabetes adoption, coupled with the need for additional capital that could dilute shareholder value and unfavorable Medicare reimbursement proposals, exacerbates the company’s financial risks and could lead to downward pressure on revenue and profitability estimates.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares